Studies have detected the expression of MYL9 in various tumors, revealing that it was upregulated in breast cancer as well as liver cancer, while downregulated in prostate cancer and bladder cancer 41-44, however, it is controversial in CRC. The gene discussed is MYL9; the disease is prostate cancer.